Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive deficits, and positive and negative symptoms. 
ABSTRACT
Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive deficits, and positive and negative symptoms. All antipsychotics currently used in clinical practice are dopamine D 2 
INTRODUCTION
Schizophrenia is a major chronic neuropsychiatric disorder affecting approximately 1% of world population. The evidence from genetic, brain imaging and clinical and pharmacologic studies indicates that schizophrenia is a heterogeneous group of disorders and suggests the lack of a single molecular event which could explain its pathophysiology (1, 2) . The etiology of schizophrenia remains still unknown, however, it seems that complex interaction between biological, environmental and genetic factors underlies this disease.
The symptoms of schizophrenia are usually divided into positive (hallucinations, delusions, disorganised thoughts and behaviours, incoherence of speech, and inappropriate emotions) and negative (social withdrawal, blunting of emotional response, anhedonia). Additionally, impairments of cognitive domains are associated with schizophrenia. The main cognitive impairments, which are considered to be a core feature of schizophrenia, include deficits in attention, working memory, verbal learning and memory, and executive functions.
It is generally accepted that blockade of dopamine D 2 receptors plays a key role in antipsychotic actions of neuroleptic drugs (3) . The discovery of antagonistic interaction between adenosine A 2A and dopamine D 2 receptors in the striatum and nucleus accumbens (see section 4.3.1.) had important implications for neuropsychiatric disorders, where dopamine neurotransmission seems to play a crucial role such as schizophrenia. Moreover, since even revised dopamine hypothesis of schizophrenia cannot fully explain its pathophysiology, research has focused on the role of other neurotransmitter systems, such as glutamate, GABA, serotonin, and also adenosine. Some review articles appeared in the last years which suggested that dysfunction of adenosinergic system may contribute to the pathophysiology of schizophrenia (4, 5) . Most of the work, however, was done regarding the role of adenosine A 1 receptors in these processes, and much less is known about the involvement of A 2A receptors. These receptors seem to be of interest also because of the existence of heteromeric complexes, formed by adenosine A 2A receptors with not only adenosine A 1 and dopamine D 2 and D 3 receptors, but also with metabotropic glutamate mGlu5 receptors (see section 4.3. and 6.1.) . The formation of such heteromeric receptor complexes in the brain increases the alternative strategies for design of novel drugs for the treatment of many disorders. Therefore, A 2A receptor agonists, which have behavioural effects in animals that are similar to those produced by atypical antipsychotics, offer a potential novel treatment of schizophrenia. The aim of this article is to review the putative role of adenosine A 2A receptors in the pathophysiology and therapy of schizophrenia.
ROLE OF DOPAMINERGIC AND GLUTAMATERGIC NEUROTRANSMISSION IN SCHIZOPHRENIA
The role of central dopamine neurotransmission in the pathophysiology and pharmacological treatment of schizophrenia is well documented. Initially, it was postulated that a hyperdopaminergic state in limbic structures was responsible for the expression of psychotic symptoms in schizophrenia (6, 7) . This hypothesis was based on experimental observations that antipsychotic drugs served as functional dopamine receptor antagonists, and their clinical efficacy correlated with their potency to block dopamine D 2 receptors (3, 8) . These findings together with the observation that administration of psychostimulants, such as amphetamine, which increase dopamine release, induce psychosis and exacerbate positive symptoms of this disorder, substantiate this hypothesis (9) . Moreover, recent neuroimaging data from PET and SPECT studies validated the dopamine hypothesis of schizophrenia showing the higher release of dopamine in response to amphetamine challenge in unmedicated schizophrenic patients vs healthy controls (10) (11) (12) (13) . The degree of dopamine release correlates positively with the severity of positive symptoms and with subsequent response to dopamine blockade. Furthermore, subjects with schizophrenia have a higher fraction of D 2 receptors occupied by endogenous dopamine than normal control subjects (12) .
The dopamine hypothesis of schizophrenia has been, however, insufficient to explain all aspects of this disease. The main problem is related to the fact that typical antipsychotics do not improve the "negative" and cognitive symptoms. In addition, many schizophrenic patients do not respond to dopamine antagonist therapy. Furthermore, some studies found that dopamine agonists might ameliorate negative symptoms (7) .
The recent hypothesis, which may help to explain the discrepancies outlined above, suggests that psychotic symptoms may results from the disturbed balance between cortical and subcortical dopamine systems. This theory links the appearance of positive symptoms to hyperactivation of dopamine system in subcortical structures, including mesolimbic system. On the other hand, the so-called negative symptoms and cognitive disturbances seem to be due mainly to the hypofunction of cortical (prefrontal cortex) dopamine system (14) (15) (16) . This suggestion has not been, however, supported by recent study of Kellendonk et al. (17) who have used a transgenic mouse model to show that prefrontal cortical function can be impaired by increased expression of dopamine in the striatum. Thus, mice overexpressing D 2 receptors in the striatum developed cognitive impairments in working memory tasks and behavioral flexibility. These cognitive deficits were shown to be related to secondary alterations in the prefrontal cortex such as the increased dopamine tissue content and dopamine turnover, as well as D 2 receptor activation in this structure, mainly associated with working memory (17) .
It is known that cortical and subcortical systems are functionally linked via the glutamatergic system. Recently, it has been postulated, based on experimental evidences, that dysfunctional glutamatergic transmission plays a major role in the pathophysiology of schizophrenia.
Involvement of glutamate N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia
Glutamate, the major excitatory neurotransmitter in the brain, regulates neuronal activity via two types of receptors: ionotropic (NMDA, AMPA, KA) and metabotropic, G-protein-coupled receptors (mGlu) (18, 19) . The latter with 8 known subtypes are classified into 3 main groups: group I (comprising subtypes 1 and 5), group II (2 and 3) and group III (4, 6, 7 and 8) mGlu receptors (19) . Receptors belonging to group I are coupled to inositol phosphate hydrolysis and are localized mainly postsynaptically (19) . Receptors belonging to group II and III, which are negatively linked to adenylate cyclase, are mostly presynaptic, and their activation inhibits glutamate release (19) .
NMDA but also non-NMDA glutamatergic receptors have been shown to play an important role in a variety of crucial brain functions, including memory and learning, synaptic and developmental plasticity, sensory information processing, and motor function (19) (20) (21) .
Results from animal studies support the notion that dysfunction of glutamatergic transmission is involved in the pathophysiology of schizophrenia (1, 20, (22) (23) (24) . Studies with uncompetitive NMDA receptor antagonists, phencyclidine (PCP) and ketamine, which can induce or mimic positive, negative and cognitive symptoms of schizophrenia, when administered to schizophrenic patients or healthy volunteers, support the involvement of NMDA receptors in schizophrenia (25-27). Moreover, clinical observations showed that atypical neuroleptics, such as clozapine alleviate psychotic symptoms evoked by ketamine (27), whereas combined administration of typical neuroleptics with agonists of glycine site of NMDA receptor, such as glycine or D-serine, alleviates schizophrenic symptoms (28-30). Additionally, alterations in expression of NMDA receptor expression have been found in the cerebral cortex, hippocampus and thalamus of schizophrenic patients (31-34).
Based on the above-mentioned observations and taking into account the existence of glutamatergic/dopaminergic interaction, it has been proposed that dopaminergic hyperactivity in the schizophrenia may be secondary to alteration in glutamatergic transmission, in particular NMDA receptor function (35). According to this view, increasing NMDA receptor activation might be expected to alleviate symptoms of schizophrenia and provide a therapeutic benefit for this disease (1, (20) (21) (22) 36 ).
The role of metabotropic glutamate mGlu5 receptors in animal models relevant for schizophrenia; interaction with NMDA receptors
Recently, it has been suggested that group I mGlu receptors, particularly mGlu5 receptor, may also contribute to schizophrenia (23, 24) . The genetic linkage studies have identified the gene encoding RGS4, a regulatory protein that affects mGlu5 receptor-mediated activation of the Gprotein, Gq, as a schizophrenia susceptibility gene (37, 38). Moreover, an increased mGlu5 mRNA level has been found in the prefrontal cortex of schizophrenic patients (39).
The mGlu5 receptors are widely distributed in the CNS, they are abundant in the striatum, nucleus accumbens, hippocampus and cereberal cortex (40, 41). Interestingly, the distribution of mGlu5 and NMDA receptors in several brain regions overlaps and both receptors can be physically connected via the chain of anchoring proteins such as PSD95, GKAP (guanylatekinase-associated proteins), Shank and Homer proteins (19, 42) . Furthermore, positive reciprocal interaction between both receptors has been demonstrated in several brain regions. It is worth mentioning that the mGlu5 receptor has been found to interact directly with adenosine A 2A receptors, forming the oligomeric complexes (see sections 4.3.3 and 6.1.2 
.).
Results obtained in mGlu5 knockout mice support the role of these receptors in animal models of schizophrenia. These mice showed sensorimotor gating deficits reflected by impaired prepulse inhibition (PPI) of the acustic startle (43-45); such deficits in PPI are also observed in schizophrenic patients (46). In turn, antagonists of mGlu5 receptors (MPEP, MTEP) given acutely neither enhanced the locomotor activity nor did they affect the PPI (45, 47-50).
Moreover, the NMDA-dependent long-term potentiation (LTP), a cellular mechanism for spatial learning, is reduced in the CA1 and dentate gyrus of the hippocampus of the mGlu5 knockout mice (51, 52). Blockade of mGlu5 receptors has been shown to impair LTP in the CA1 and dentate gyrus of the hippocampus as well as to induce deficits in working memory and reference memory performance (23, 53, 54 Based on the existing interaction between mGlu5 and NMDA receptors (57-62), antagonists of mGlu5 and NMDA receptors can act in a cooperative manner to produce behavioural impairments. Thus, blockade of mGlu5 receptors has been found to potentiate locomotor activity and stereotypy evoked by PCP or MK-801 in rats and mice (45, 48-50, 63). Moreover, aggravation of learning and memory impairment evoked by PCP and MK801 as well as potentiation of PCP-and MK801-induced PPI disruption have been demonstrated (49, 56 ). A putative mechanism underlying behavioural effects of mGlu5 and NMDA receptor antagonists may be due to the fact that blockade of mGlu5 receptors enhanced the MK-801-induced firing activity in the prefrontal cortex (PFC) of rats, the structure which is critical for cognitive functions and has high density of mGlu5 receptors (63-67).
In summary, since blockade of mGlu5 receptors potentiates the effects of uncompetitive NMDA receptor antagonists on cognitive and psychotic-like symptoms in animals, it seems reasonable to suggest that mGlu5 receptor agonist/positive modulators may represent a novel approach to antipsychotic drug development. In agreement with this suggestion, recent studies have found that intracerebroventricular administration of the selective mGlu5 receptor agonist, CHPG or systemic injection of CDPPB, the mGluR5 positive modulator, reverse locomotor activity and/or deficit of PPI evoked by amphetamine in rodents (68, 69).
ADENOSINE METABOLISM AND RECEPTORS
In the last years, research regarding neuropsychiatric disorders has been focused on the role of other neurotransmitters and neuromodulators, such as GABA, serotonin, acetylcholine and adenosine. Adenosine, an endogenous purine nucleoside present in all mammalian tissues, modulates a variety of important physiological processes. The neuromodulatory role of adenosine in the CNS has been proposed to be exerted mainly through the control of neurotransmitter release (70-72).
Adenosine is formed intracelullarly from degradation of AMP through 5'-nucleotidase, or extracelullarly by the metabolism of released nucleotides Figure 1 . Adenosine metabolism. Adenosine is formed intracelullarly from 5'-AMP by the cytosolic 5'-nucleotidase, or extracelullarly by the metabolism of nucleotides released through the action of ecto-5'-nucleotidase. Hydrolysis of SAH by SAH hydrolase may be another intracellular source of adenosine. Extracellular adenosine is primarily inactivated by uptake through the transporters which are mainly bi-directional, followed by either phosphorylaton to AMP by AK or to a lesser degree, deamination to inosine by ADA. Another possible catabolic pathway, however, of minor significance, is a reversible reaction catalysed by SAH hydrolase, leading to formation of SAH from adenosine and L-homocysteine (for more details see ref. 73, 74) . Abbreviations: ADA, adenosine deaminase; AK, adenosine kinase; A 1 , A 2A , A 2B and A 3 -adenosine receptors; NT, nucleoside transporter; SAH, S-adenosylhomocysteine through the action of ecto-5'-nucleotidase ( Figure  1 ) (73). Hence, its formation depends upon ATP breakdown and synthesis. The main mechanism implicated in adenosine release, facilitated diffusion, involves specialized nucleoside transporters (73). These transporters are mainly bi-directional, and keep the extracellular concentration of adenosine in equilibrium. Hydrolysis of Sadenosylhomocysteine (SAH) by SAH hydrolase (Figure  1 ), may be another inracellular source of adenosine, however, this pathway does not significantly contribute to adenosine production in the brain (73). Extracellular adenosine is primarily inactivated by uptake across the neuronal cell membrane, followed by either phosphorylaton to AMP by adenosine kinase (AK) or to a lesser degree, deamination to inosine by adenosine deaminase (ADA). Both AMP and inosine are less active than adenosine at the adenosine receptors (73). Another possible catabolic pathway is a reversible reaction catalysed by SAH hydrolyse, leading to formation of SAH from adenosine and L-homocysteine, however, it represents only a minor pathway of adenosine catabolism under basal conditions ( Figure 1) In the striatum, A 2A receptors are homogeneously distributed throughout the lateral and medial parts and display dense labelling of the neuropil (92). Studies at the ultrastructural level showed that striatal terminals expressing A 2A receptors accounted for 25% of the labelled elements (92, 95). These presynaptic receptors may facilitate both excitatory glutamatergic, and inhibitory GABAergic striatal transmission. However, the majority of A 2A receptors were found on postsynaptic elements in the striatum (92, 95), a structure known to be characterized by a high compartmentalization and neurochemical segregation (96, 97) . Two distinct GABAergic projection pathways are known to oppositely regulate basal ganglia output. Activation of the direct GABAergic pathway (striatonigral) containing substance P and dynorphin facilitates motor behaviour by disinhibiting cortical and brainstem motor areas, whereas stimulation of the indirect GABAergic pathway (striatopallidal) containing enkephalin, leads to inhibition of motor behaviour (96, 97) . In line with this neurochemical segregation, dopamine D 1 receptors are almost exclusively located on the direct pathway whereas D 2 receptors are located together with A 2A receptors on the indirect pathway (92, 95, 96, 98, 99) .
In the nucleus accumbens (the so-called ventral striatum), A 2A receptors followed the same pattern as the dopamine D 2 receptors, and the shell of the nucleus accumbens displayed a density of adenosine A 2A receptors about 40% lower to that in the dorsal striatum (92).
Additionally, the co-expression of adenosine A 2A and A 1 receptor mRNAs was found on about 25% of the glutamatergic nerve terminals of the rat hippocampus (100). These results support the previous suggestion that such co-localization may be the basis for the interaction between A 2A and A 1 receptors in the control of glutamate release (100) (101) (102) (103) . It is, however, an open question if such control of glutamate release is also present in other brain areas, such as the cerebral cortex or the striatum, where both receptors are known to be present and co-localized in the same nerve terminals. Functional data revealed that there are also populations of nerve terminals which are only regulated by A 2A receptors but not by A 1 receptors, such as GABAergic terminals of the hippocampus (104) and the striatum (105) . Thus, the distribution of A 1 and A 2A receptors is likely to be heterogeneous in different types of nerve terminals throughout the brain.
Adenosine A 2A receptors and dopamine release
Early in vitro studies of the regulation of ( 3 H) dopamine release from striatal slices showed that adenosine (106) and selective agonists of both A 1 and A 2A receptors inhibited electrically-evoked ( 3 H) dopamine release (107). The results obtained so far using in vivo brain microdialysis on the effects of adenosine A 2A agonists and antagonists on dopamine release in the striatum and nucleus accumbens appear conflicting. Thus, the A 2A agonists, CGS21680 and CPCA as well as caffeine increased the release of dopamine in the striatum (108) (109) (110) . In contrast, Okada et al. (110) (111) (112) reported that A 2A agonists and antagonists did not affect striatal dopamine release unless adenosine A 1 receptors had been previously blocked.
Recently, however, Quarta et al. (113, 114) showed using in vivo microdialysis, that local perfusion of the A 2A receptor agonist CGS21680 or A 1 receptor antagonist, CPT, elicited significant increase in extracellular level of dopamine as well as glutamate, in the shell of the nucleus accumbens. In turn, systemic administration or local perfusion of the nonselective adenosine receptor antagonist, caffeine also significantly increased extracellular levels of dopamine and glutamate in this structure (113, 115) . The observed effects of caffeine as well as selective A 1 and A 2A receptor ligands on the dopamine release seem to be under the stimulatory control of extracellular glutamate and to depend on the activation of NMDA receptors (113, 114, 116) . On the basis of the above results, a hypothesis regarding the modulatory role of adenosine on dopamine and glutamate release in both the dorsal and ventral striatum was proposed, taking into account the antagonistic A 1 /A 2A receptor interaction, by which stimulation of A 1 receptors decreases the effects of A 2A receptor stimulation on both dopamine and glutamate release in the striatum (112) (113) (114) 117) . It was suggested that under basal conditions, when the level of endogenous adenosine was low, its effect on A 1 receptors predominated, which masked the effects produced by A 2A receptor stimulation (113, 114) . However, under conditions of stronger adenosine release, a sufficiently stronger stimulation of A 2A receptors could override the inhibition imposed by A 1 receptors and, thereby inducing both glutamate and dopamine release (113, 114) .
In contrast, Aquas et al. (118) did not find any effect of caffeine, given intravenously or intraperitoneally, on the dopamine release in all the subdivisions of the nucleus accumbens. Similarly, intravenous administration of selective A 1 and A 2A antagonists, DPCPX, and SCH58261, respectively, did not change the dialysate dopamine (118) . In the recent work, Quarta et al. (113) observed, however, a significant decrease in the extracellular levels of dopamine and glutamate in the shell of the rat nucleus accumbens after acute, systemic administration of A 2A antagonist, MSX-3. Moreover, this compound counteracted the release of both dopamine and glutamate induced by systemic administration of caffeine (113) . Furthermore, chronic exposure to caffeine in the drinking water resulted in tolerance to the effects of systemic injection of caffeine on extracellular levels of dopamine and glutamate in the nucleus accumbens shell, which may explain its weak, addictive properties and atypical psychostimulant profile (113) .
It seems, however, interesting that intravenous administration of caffeine which, according to Aquas et al. (118) , failed to affect dopamine release in the nucleus accumbens, dose-dependently increased dopamine dialysate concentrations in the medial prefrontal cortex; an effect which might account for the reinforcing psychostimulant properties of this compound (118, 119) . Moreover, no changes in dopamine in the prefrontal cortex were seen in rats treated with caffeine for 7 days, when animals became tolerant to its locomotor stimulating effects (118) . Furthermore, chronic exposure to caffeine in drinking water resulted in tolerance to the effects of systemic injection of caffeine on extracellular levels of dopamine and glutamate in the nucleus accumbens shell, which may help to explain its weak, addictive properties and atypical psychostimulant profile (113).
Heteromeric complexes formed by adenosine A 2A receptors
A growing body of evidence indicates the existence of G protein-coupled receptor (GPCR) heteromerization. Such heteromers are presently regarded as a molecular basis for the known direct or indirect (via adapter proteins) intramembrane receptor/receptor interactions. Understanding of the biology of the A 2A receptor, particularly its molecular interactions with other neurotransmitter receptors, is of great clinical importance since these receptors are molecular targets for numerous therapeutics including antipsychotics and antiparkinsonian ones.
Adenosine A 2A and dopamine D 2 heteromers
Evidence for antagonistic interaction between A 2A /D 2 receptors within the striatum has been extensively reviewed elsewhere (120) (121) (122) .
A few years ago the first evidence was presented in neuronal and fibroblast cell lines that adenosine A 2A and dopamine D 2 receptors form functional heteromeric Numerous biochemical and behavioural studies provided evidences for the existence of distinct negative interaction between adenosine A 2A and dopamine D 2 receptors, located on the same GABAergic neurons in the dorsal striatum, which allows both dopamine and adenosine to modulate the activity of output pathways (120) (121) (122) 
Adenosine A 2A and dopamine D 3 heteromers
It is well known that many antipsychotic drugs, such as haloperidol, clozapine or olanzapine, block both dopamine D 2 and D 3 receptors, and that D 3 receptors are preferentially expressed in the ventral striatum (136, 137) . Therefore it has been suggested that the particularly strong interaction between adenosine and dopamine receptors found in the ventral vs. dorsal striatum (121, 131) (140, 145) and the quinpiroleinduced turning behaviour in 6-OHDA-lesioned rats (145, 146) . A strong functional synergistic interaction at the level of extracellular signal-regulated kinase (ERK1/2) phosphorylation and dopamine-and cAMP-regulated DARPP-32 phosphoprotein, as well as at the level of immediate early gene (c-fos) expression in HEK-293 cells, transiently co-transfected with A 2A and mGlu5 receptors was found after their co-activation ( Figure 3 ) (144, 147) . Therefore, it seems that a major biochemical site of integration responsible for the synergistic interaction between A 2A and mGlu5 receptors might be at the mitogenactivated protein kinase (MAPK) level (Figure 3) . However, the lack of synergistic interaction between A 2A and mGlu5 receptors at the level of second messenger (cAMP and (Ca 
Heteromeric complexes formed by adenosine A 2A and A 1 receptors
Very recently, heteromeric complexes between adenosine A 1 and A 2A receptors have been discovered by co-immunoprecipitation, BRET and FRET techniques in co-transfected cells (150) . Radioligand-binding experiments in co-transfected cells and rat striatum showed that a main biochemical characteristic of the A 1 /A 2A receptor heteromer is the ability of A 2A receptor activation to reduce the affinity of the A 1 receptor for agonists (150) . Interestingly, the same is not true for the activation of the A 1 receptors, which does not alter the binding characteristic of A 2A receptor (150) . The ability of A 2A receptors to control A 1 receptors in such heteromers was further confirmed functionally, showing, upon formation of heteromers, the significant reduction in the A 1 -induced intracellular calcium peak, obtained by preincubation with a selective A 2A receptor agonist (150) .
At present, however, it is still an open question whether the formation of such A 1 /A 2A receptor heteromers might play a physiological role in native brain preparations. This question is of major relevance since the involvement of GPCR heteromers in pathophysiological processes in the CNS remains still unknown, despite substantial evidence for their presence in native brain preparations. Recently, Ciruela et al. (2006) proposed that A 1 /A 2A receptor heteromers might exert a fine-tuning modulation of glutamatergic neurotransmission in the striatum. This hypothesis was based on the well-known opposite role of A 1 and A 2A receptors in the regulation of glutamate release in the striatum and hippocampus, where both receptors are present on presynaptic terminals (102, 103, 113) . Since it is already known that glutamatergic terminals in the striatum establish synaptic contacts with the dendritic spines of the GABAergic efferent neurons, such heteromeric complexes may also control the activity of output neurons of this structure. Furthermore, it has been shown that A 1 /A 2A heteromers constitute a unique target for caffeine and that chronic caffeine treatment leads to modifications in the function of the A 1 /A 2A receptor heteromer that could underlie the strong tolerance to the psychomotor effects of caffeine, the most widely used psychoactive compound in the world (89, 150).
ADENOSINE A 2A RECEPTORS IN SCHIZOPHRENIA
The discovery of A 2A /D 2 interaction in the dorsal and ventral striatum has important implications for neuropsychiatric disorders, where dopamine neurotransmission seems to play a crucial role. Moreover, the dopamine hypothesis of schizophrenia cannot fully explain its pathophysiology. Therefore, recent research has focused on the role of other neurotransmitter systems such as glutamate, GABA, serotonin, and also adenosine dysfunction of the latter has been recently suggested by Lara et al. (4, 5) (162) failed to find an association between A 2A receptors and schizophrenia. Of interest, however, is the fact that the G-protein coupled to A 2A receptor, Golf, which is mainly expressed in the nucleus accumbens and striatum, is a candidate gene for schizophrenia (163) . Moreover, the Golf knockout mice showed a reduced locomotor activation by caffeine and amphetamine compared to wilde type mice (164) .
Likewise, postmortem studies support the role of A 2A receptors in the pathophysiology of schizophrenia by showing an increased binding of ( 3 H)-CGS21680 in the putamen and caudate of schizophrenic patients (165). Such a statistically significant increase in the specific binding was observed in two groups of schizophrenic patients: (1) "off-drug" individuals who had received no antipsychotics for more than 40 days before death, and (2) "on-drug" patients who had been treated with antipsychotics almost until death. Furthermore, an increased number (Bmax) of A 2A receptors and their increased affinity (Kd) in the post mortem striatum of schizophrenic patients were reported by Deckert et al. (166) ; however, those authors also observed a correlation with the dose of previous antipsychotic medication. Therefore, it seems plausible that the observed up-regulation of A 2A receptors in schizophrenia may be due to the antipsychotic treatment rather than the disease itself, since similar increase in the number of A 2A receptors were seen e.g. after chronic haloperidol treatment in the rat striatum (167).
Studies on animals carried out in the last years delivered premises that suggested the role of adenosine A 2A receptors in the pathophysiology of schizophrenia and also in the effect of antipsychotic drugs, which are mainly D 2 receptors antagonists. The following evidences were among the first: occurs not only in the dorsal but also in the ventral parts of the striatum i.e. nucleus accumbens, a structure that is thought by some researchers to be important for the antipsychotic action of neuroleptics (131, 168) . Both dorsal and ventral striatum are components of anatomically and functionally differentiated circuitry (131, 169, 170) , and the functional role of dopamine is different in both parts of the striatum (171 Caffeine, a psychoactive drug most commonly consumed in coffee, tea, cocoa beverages, chocolate and soft drinks, is a non-selective adenosine antagonist. It has been suggested that schizophrenic patients have a higher-than-average intake of caffeine, but the findings are inconsistent in this respect (172) (173) (174) (175) (176) (177) . A recent study by Gurpegui et al. (178) , showed that daily caffeine intake was less frequent in schizophrenic patients than in controls, but among caffeine consumers, a heavy caffeine intake (>200 mg/day) was significantly more frequent in schizophrenics than in controls. Additionally, some earlier reports showed that high intakes of caffeine can produce psychoses in healthy subjects (176, 179) and may worsen psychotic symptoms in schizophrenic patients (180) (181) (182) . However, given that caffeine is the most widely used substance in the world, it appears that caffeine-induced psychoses are extremely rare. Moreover, Hughes et al. (176) suggested that caffeine elimination from patients with schizophrenia did not appear to make them better or worse. In line with this opinion, it was shown that switching from caffeinated to decaffeinated beverages had no effect on schizophrenic symptoms (173, 175, 183) . Likewise, Gurpegui et al. (174) found no relation between caffeine intake and schizophrenic symptomatology. However, since De Freitas et al. (181) showed that a switch to decaffeinated coffee was associated with a decrease in hostility and suspiciousness, and was reversed when regular coffee was reintroduced, the possibility of a relationship between caffeine intake and schizophrenia symptomatology cannot be completely ruled out. In addition, caffeine was shown to ameliorate the negative symptoms, e.g. it improved mood and decreased withdrawal and was found to improve extrapyramidal symptoms of neuroleptics (180) . Interestingly, a high dose of caffeine did not increase anxiety scores in schizophrenic patients (176).
The effects of adenosine A 2A agonists in animal models relevant to schizophrenia
Stimulation of A 2A receptors was shown to reduce the psychomotor stimulating effects of dopamine receptor agonists such as amphetamine, including stereotypies at doses failing to evoke catalepsy (131, 152, 184) . Moreover, A 2A agonist, CGS21680 was shown to block conditioned avoidance responding in rats and to be effective, similarly to haloperidol and raclopride, in the apomorphine-induced climbing mouse assay (185, 186) . Systemic administration of CGS21680 was also shown to counteract apomorphine-induced stereotypies and quinpirole-induced yawning but not grooming induced by the selective D1 agonist, SKF38393 (187), which supported the potential antipsychotic-like effect of this compound. Furthermore, in vivo microdialysis studies showed that co-infusion of A 2A receptor agonist and D 2 receptor antagonist into the nucleus accumbens at ineffective concentrations, produced a significant increase in the level of extracellular GABA in the ventral pallidum (131, 151) . In addition, systemic, intrastriatal or intraaccumbal administration of CGS21680, a selective A 2A receptor agonist, to rodents reduced spontaneous locomotor activity, and at higher doses, induced catalepsy (152, 186, (188) (189) (190) (191) .
Taking into account the results, showing an increased dopamine release in the nucleus accumbens shell after stimulation of A 2A receptors, it is rather difficult to explain these reversing effects of CGS21680 on the amphetamine-induced locomotor activity and stereotypy. In schizophrenia as well as after injection of amphetamine, which serves as an animal model relevant to this disease, dopamine release in subcortical structures was demonstrated to increase (13, 192) . Therefore, after the administration of both, amphetamine and A 2A agonists, rather an additive, stimulant effect on the behaviour should be seen. It should be, however, mentioned that effects of A 2A receptor stimulation on dopamine and glutamate release seem to depend also on the basal level of adenosine and the existence of antagonistic interaction with A 1 receptors (see also sections 4. 2. and 4.3.4.) . Moreover, an action of CGS21680 compounds also on the A 1 receptors cannot be fully excluded, since the affinity of this compound for A 2A receptors is about 10 times higher than to A 1 receptor (193) . Furthermore, an action of A 2A receptor stimulation on the dopamine transporter (DAT) cannot be rejected since some changes in the binding to DAT as well as in the DAT mRNA level were found in A 2A knockout mice (194) . In order to solve this problem, further studies are needed. However, a postsynaptic mechanism, involving antagonistic interaction between A 2A and D 2 receptors can help to explain the attenuation of amphetamine-induced effects by CGS21680 as this compound was shown to reduce the affinity of D 2 receptors for dopamine in the nucleus accumbens (128).
The antipsychotic-like profile of CGS21680 compound was also confirmed in non-human primates, Cebus appella monkeys (195) . In those monkey a reversal of apomorphine-induced psychosis-like symptoms was observed at doses that did not elicit extrapyramidal sideeffects (195) . All the above mentioned results suggests that A 2A agonists show the behavioural profile of antipsychotic drugs. However, it is unclear whether they possess socalled "atypical" antipsychotic profile. Studies of Kafka and Corbett (186) and Hauber and Munkle (191) suggested a profile of A 2A agonists similar to classic D 2 receptor antagonists rather than atypical neuroleptics since in behavioural studies they induce effects similar to those produced by D 2 antagonists (e.g. catalepsy). On the other hand, atypical profile of A 2A agonists was suggested by the following data:
A stronger antagonistic A 2A /D 2 interaction was observed in the ventral striatum, as in the presence of CGS21680, dopamine exhibited lower efficacy in displacing the radiolabelled D 2 receptor antagonist from the rat ventral striatum, especially in the nucleus accumbens (131, 151) . (2) Studies of Rimondini et al. (152) showed that the ED 50 of CGS21680 for inducing catalepsy was more than 10-times higher than the ED 50 for depressing exploratory activity in rats treated systemically. (3) A selective increase in the expression of the immediate early gene, c-fos, in the shell of the nucleus accumbens, which is a part of the ventral striatum, but not in the dorsolateral striatum, was found after the systemic administration of the selective adenosine A 2A agonists, CGS21680 and HE-NECA (133 (196) , which additionally suggests the contribution of A 2A receptors to the therapeutic effects of antipsychotics.
Adenosine A 2A receptor agonists were also shown to counteract many effects of NMDA receptor antagonists such as PCP, ketamine and MK-801 in animals. In particular, the stimulation of A 2A receptors was shown to reverse ketamine-and MK-801-induced motor activity in mice (197, 198) . CGS21680 antagonizes also the locomotor stimulatory action of PCP at doses lower, than that, necessary to reduce the amphetamine-induced hyperactivity in rats (152) . Similar effects have been observed after administration of atypical neuroleptics (199) . Since the effects of NMDA antagonists are considered to be a pharmacological model of schizophrenia, the interaction between adenosine and the glutamatergic system may have therapeutic implications.
Previously it has been suggested that "atypical" antipsychotic drugs including clozapine, olanzapine, seroquel or remoxiprid, in contrast to classic neuroleptics such as haloperidol, reversed the effects of PCP in the prepulse inhibition (PPI) of the startle reflex, an animal model relevant to schizophrenia (200) (201) (202) (203) (204) . Moreover, the deficit in PPI induced by PCP was reversed by stimulation of adenosine A 2A receptors by CGS21680 at doses, devoid of motor side-effects (205, 206) . Thus, CGS21680 was without effect on catalepsy, muscle rigidity and rotarod performance in rats, as well as on the proenkephaline mRNA expression in the striatum, estimated by in situ hybridization (206) .
The putative mechanism by which adenosine A 2A receptor stimulation reverses the effects of PCP and other uncompetitive NMDA receptor antagonists has not been satisfactorily elucidated as yet. Nevertheless, it is known that mesolimbic dopamine neurotransmission is involved in these effects and that PCP stimulates dopamine neurotransmission, particularly within the nucleus accumbens (207) (208) (209) . Therefore, it might be suggested that CGS21680 attenuates the PCP effect by inhibiting dopamine transmission via antagonistic A 2A /D 2 interaction. However, the blockade of dopamine D 2 receptors by neuroleptics does not influence the PCP effect in this model (200, 202, 204) . Also, Sills et al. (205) did not observe any influence of CGS21680 given systemically on the apomorphine-and amphetamine-induced deficits in PPI in rats which do not support this hypothesis. Another plausible explanation is based on the existence of similar or synergistic effects of NMDA and A 2A receptors at the cellular level. It is already known that both these receptors are involved in the haloperidol-induced early gene c-fos expression in the striatum (210) . According to Nash and Brotchie (211) , both NMDA and A 2A receptors share a common second messenger signalling pathway within the striatum, since the stimulation of either NMDA or A 2A receptors leads to increases in cAMP levels via activation of the same adenylyl cyclase. Therefore, it seems that stimulation of adenosine A 2A receptors may counteract the effects induced by PCP-mediated NMDA receptor blockade, including the reversal of PCP-induced PPI impairment.
All the above-mentioned results support the hypothesis of antipsychotic profile of A 2A receptor agonists, qualitatively similar to dopamine antagonists. However, it should be mentioned that many of the abovedescribed effects of A 2A agonists were also shared by adenosine A 1 receptor agonists. Nevertheless, whereas A 2A agonists display a clear separation between doses inducing catalepsy and motor incoordination, A 1 agonists induce ataxia and sedation at similar doses. Finally, despite the promising results obtained in experimental animals, A 2A receptor agonists such as CGS21680 are known to induce a marked hypotension, and tachycardia, which limits the clinical development of these compounds (212).
The effects of adenosine A 2A antagonists in animal models of schizophrenia
Similarly to amphetamine and NMDA receptor antagonists, caffeine and theophylline were shown to produce psychomotor stimulant effects by enhancing locomotor activity and schedule-controlled behaviour, which was reversed by antipsychotics (131, (213) (214) (215) (216) . However, it should be keep in mind, that only low doses of caffeine increase motor activity in mice and rats, while higher doses are depressant and inhibit it (119, 217, 218) . These high doses of caffeine can also produce conditioned place aversion in rodents (219) . The psychostimulant effect of caffeine was shown to be mediated by antagonism at both adenosine A 1 and A 2A receptor levels (220-222), whereas adenosine A 2A receptors seem to play a fundamental role in caffeine-mediated motor behaviour (223, 224) . Moreover, methylxanthines potentiate the motor behaviour induced by direct and indirect dopamine agonists and block the effects of dopamine D 2 antagonists (225) (226) (227) . In contrast, caffeine given for seven days was shown to abolish the hyperlocomotion and cognitive deficits induced by MK-801, without influencing the amphetamine-induced locomotor activity in rats (228) .
The results regarding the locomotion, obtained in studies with selective A 2A antagonists are rather controversial. Namely, increased locomotor activity was shown after systemic or intraaccumbal (into the core but not shell part) injection of selective adenosine A 2A antagonists, like SCH58261, KF17837, KW6002 (229) (230) (231) (232) (233) . Furthermore, locomotor activity produced by subthreshold dose of ketamine or dizocilpine in mice, was potentiated by selective adenosine A 2A antagonists and by theophylline (197, 198) . SCH58261 increased, besides basal locomotion, also the apomorphine-induced motor stimulation, with no signs of tolerance after repeated treatment (234 Besides locomotion, both caffeine given at low doses, and the selective A 2A receptor antagonist were shown to potentiate the amphetamine-induced stereotypy (184) and to elicit the place preference in rats (219, 222, 230) . The latter effect was seen at doses increasing the dopamine overflow in the nucleus accumbens (230) .
Studies on the influence of caffeine and theophylline, on the responses of sensorimotor gating, such as the P50 evoked potential and prepulse inhibition, produced conflicting results. In humans, theophylline was shown to impair sensory gating measured with the P50 paradigm in healthy volunteers, resembling the findings in schizophrenic patients (238) . However, caffeine did not influence the PPI in normal control subjects who were the minimal or heavy coffee drinkers (239) . In accordance with these observations, Flaten and Elden (240) described the lack of effect of caffeine on startle magnitude or PPI in relatively heavy caffeine drinkers.
In rats, caffeine did not affect significantly the PPI, but decreased the startle amplitude (241) . Koch and Hauber (242) in a subsequent study found that theophylline at a dose which had no intrinsic effect, potentiated the disruption to PPI, caused by a submaximal dose of apomorphine. This effect was suggested to be mediated rather by A 1 receptors since co-administration of A 1 , but not A 2A selective agonist, abolished the effect of theophylline (242) . The lack of effect of A 2A blockade on the PPI has been confirmed in studies using the selective A 2A receptor antagonist, KW6002 (243) . This compound was inactive in PPI across a wide range of doses when given alone and had no effect on the disruption of PPI induced by the D 2 receptor agonist, pergolide (243) . However, a disruption of prepulse inhibition of the startle reflex was observed by Nagel et al. (231) after bilateral intraaccumbal infusion of selective A 2A antagonist, MSX-3. Additionally, the A 2A knockout mice showed reduced PPI and startle habituation (244).
5.3.
Behavioural sensitization induced by psychostimulants Behavioural sensitization, which is known to develop after repeated administration of psychostimulants such as amphetamine, may represent the neural adaptation underlying some features of psychosis and addiction in humans (66, [245] [246] [247] . Amphetamine was also shown to induce sensitization in rodents (247) and in non-human primates (248, 249) . Indeed, sensitization of dopaminergic functions has been proposed to be a core pathophysiological process leading to schizophrenia since it produces neurochemical and behavioural characteristics seen in some schizophrenics (66, 250, 251) . Thus, reduced prepulse inhibition of the acoustic startle reflex and profound, long-lasting impairment in working memory were found in amphetamine-sensitized animals (66, 251). Although the mechanisms underlying the process of sensitization are not fully understood as yet, evidence suggests engagement of dopaminergic neurotransmission (245) .
Recently, the important role of A 2A receptors in the development of amphetamine-induced sensitization was also shown in mice lacking A 2A receptors but with preserved dopamine innervation and receptors (252) . These mice showed attenuated response to amphetamine and cocaine but not to selective dopamine D1 or D 2 agonists (252). Furthermore, results derived from experiments with A 2A knockout mice, including a forebrain-specific conditional (Cre/loxP system) knockouts, suggest a critical role for these receptors in the development of amphetamine-induced behavioural sensitization (232, 252) . These results together with the existing and well described A 2A /D 2 receptor heteromerization, have been suggested to open new directions in the understanding and treatment of schizophrenia (120, 246) .
Besides amphetamine, subchronic caffeine given intermittently in low doses also was shown to produce behavioural sensitization to the motor stimulant effects induced by dopamine agonists in rats (227, (253) (254) (255) (256) (257) . The caffeine-induced sensitization was associated with reduced levels of A 2A receptors and early-gene zif268 mRNAs in enkephaline-positive neurons in the striatum and nucleus accumbens (257) . Therefore, these results support the previous suggestions regarding the involvement of A 2A receptors in the adaptive changes, which produce behavioural sensitization to amphetamine and caffeine.
Adenosine A 2A receptors and cognitive processes
While positive and negative symptoms of schizophrenia have long been considered as the hallmark of schizophrenia, recent clinical studies emphasized cognitive dysfunction as a primary features of this disorder, because they are detectable even before the onset of psychosis (66, 258, 259). Cognitive impairments are found across most domains (e.g., attention, working memory, verbal fluency, processing speed, executive functions, verbal memory) in the vast majority of schizophrenic patients. These deficits may become more marked in later life and are an important treatment target, because such deficits are the best predictor of a patient's level of interpersonal skills, occupational functioning, and self care (258) .
It has already been suggested that adenosine plays an important modulatory role in learning and memory processes by regulating synaptic transmission, neuronal excitability and synaptic plasticity including such processes as hippocampal long-term potentiation (LTP) and longterm depression (LTD) (260) (261) (262) (263) (264) , which presumably underlie certain forms of learning and memory (265) (266) (267) . Previous studies have demonstrated that adenosine receptor agonists, mainly of A 1 type, disrupt learning and memory in rats and mice (268) (269) (270) while antagonists, either nonselective or selective, facilitate learning and memory in the passive avoidance task (271-274), the step-down inhibitory avoidance task (273) and the water maze task (275, 276) . However, the specific role of A 2A receptors in learning and memory is still unclear, with A 1 receptors apparently having a more dominant role (274, 276) .
Recently, however, new data supporting the role of A 2A receptors in these processes have been published, namely acute stimulation of A 2A receptors disrupted, and blockade of A 2A receptors enhanced the short-term social memory in rats (277) . A similar improvement in social memory was found after acute caffeine administration (277) . In line with these findings, infusion of A 2A receptor antagonist, ZM241385 directly into the posterior cingulate cortex did not affect retrieval of inhibitory avoidance longterm memory. On the contrary, stimulation of A 2A receptors after infusion of CGS21680 into the posterior cingulate cortex induced an amnesic effect at all doses tested, which was blocked by co-infusion of A 2A antagonist (278) . Additionally, facilitative effects with regard to reference memory were found by Hauber and Bareiss (276) after chronic theophylline in rats. Furthermore, recent results obtained by Prediger et al. (279) supported the role of A 2A receptors in learning and memory processes showing reversal by caffeine and ZM241385 of social memory impairment in spontaneously hypertensive rats. These compounds were also shown to reverse the age-related deficits in olfactory discrimination and short-term social memory in rats (280) . All the above-mentioned results together with the data obtained by Wang et al. (281) , showing an improvement of spatial recognition memory, measured in the Y-maze in mice lacking A 2A receptors, support the cognitive enhancing effects of adenosine A 2A receptor blockade.
However, much less is known regarding the role of A 2A receptors in animal models of working memory. Adenosine A 2A antagonists were shown to reverse the detrimental effect induced by MK-801 in a model of working memory in mice (282) . On the other hand, Hooper et al. (283) did not show any effect of A 2 stimulation on spontaneous alternation, a model of working memory in mice. However, in a very recent study Gimenez-Llort et al. (284) showed for the first time deficits in working memory in the new transgenic rat strain, with overexpression of the human A 2A receptors. The authors used a set of behavioural tests for spatial reference and working memory and also found that these memory deficits were correlated with increased levels of A 2A mRNA and A 2A receptor protein, as well as of increased A 2A receptor binding function, especially in regions of the cerebral cortex, including the prefronatal cortex, a key region in the functional neural networks of working memory and its deficits (15) . The A 2A receptor overexpression found in other structures such as the parietal cortex, hippocampus, basal ganglia, and thalamus, regions also known to be involved in working memory deficits (66, 285), could be of relevance for this deficits. On the other hand, a significant down-regulation of D 2 and mGlu5 receptors found in the striatum of these transgenic rats may suggest involvement of this structure in mediating alterations in working memory. Such downregulation of D 2 and mGlu5 receptors was suggested to be related to the selective ability of A 2A receptors to form heteromeric complexes with both these receptors (89, 123, 124, 144) . On the basis of these results and existing adenosine/dopamine interactions, Gimenez-Llort and coworkers (284) suggested that these transgenic rats, overexpressing adenosine A 2A receptors could provide an useful animal model for some cognitive disruptions at the level of prefrontal cortex.
SUMMARY AND PERSPECTIVES
The idea that adenosine A 2A receptors may be of interest for the treatment of schizophrenia has been founded on the studies showing the antagonistic interaction between adenosine A 2A and dopamine D 2 receptors and from the subsequent findings that both the receptors may form heteromeric complexes. Based on this intramembrane A 2A /D 2 interaction, some suggestions have been put forward about A 2A agonists as putative antipsychotic drugs since the enhancement of A 2A receptor activity could be relevant for the treatment of schizophrenia, where inhibition of dopamine D 2 action may be beneficial. In line with this suggestion, an involvement of A 2A receptors in the antipsychotic effects of neuroleptics such as clozapine and haloperidol was found. However, A 2A agonists were shown to have amnesic effects in animal models of learning and memory, which does not support this previous suggestion. Moreover, it remains unclear whether A 2A receptor agonists possess a sufficient safety margin or whether their hypotensive effects or extrapyramidal side-effects would limit their therapeutic utility as antipsychotic agents. In addition, some peripheral adverse effects were also observed which, at present, limit their use in the clinical trials.
On the other hand, antagonists of A 2A receptors, both selective and nonselective such as caffeine, which are known to produce the antiparkinsonian and neuroprotective effects in Parkinson's disease, failed to produce behavioural effects resembling negative symptoms of schizophrenia, moreover, they showed lack of effects or even some cognitive enhancing properties in animals. Taking into account all the discrepancies discussed above, the usefulness of A 2A receptor agonists/antagonists and their limitations, as well as the fact that all results indicating involvement of A 2A receptors in schizophrenia stem from animal experiments only, it seems that further studies are ncessary to elucidate their role in the pathophysiology and treatment of schizophrenia.
Finally, it should be mentioned that Lara et al. (5) proposed recently a model of adenosine dysfunction in schizophrenia, which takes into consideration the dopamine and glutamate hypothesis. This "two hits" hypothesis, based on the neurobiological role of adenosine in the CNS, suggests that after a transient increase in adenosine release due to perinatal events (such as hypoxia, virus), a decreased adenosinergic activity persists in schizophrenic patients due to partial loss of A 1 receptors (see 5). Therefore, the pharmacological treatments enhancing adenosinergic activity, especially through A 1 receptors, might be concordant with this hypothesis, effective for alleviating symptoms of schizophrenia. In line with this suggestion, allopurinol, which may indirectly increase the level of adenosine, was shown to be effective in the clinical trial (286, 287, see 6.1 below).
1. Adenosine in clinical trials for schizophrenia
To date, A 2A agonists or antagonists have not been examined in clinical trials. The results of pilot clinical studies indicate the use of substances which can enhance the extracellular level of adenosine. Such treatment -when applied together with neuroleptics -may be of therapeutic value in reducing psychopathological symptoms in schizophrenic patients. A few clinical trials were conducted with the adenosine transporter inhibitor, dipyridamole and inhibitor of purine degradation, allopurinol. When dipyridamole was given together with haloperidol to schizophrenic patients, some beneficial effects on positive symptoms, thought to be due to adenosine-dopamine interactions were seen (288) . Moreover, administration of allopurinol as adjunctive therapy to schizophrenic patients, previously resistant to typical antipsychotics, produced the clinically relevant improvement in about half of the patients (289) . Similar results were obtained by Brunstein et al. (286) who administered allopurinol to patients undergoing antipsychotic treatment and found improvement in 9 out of the 22 patients who completed this study. Response was more pronounced for positive symptoms and responders had shorter illness duration (286) . In addition, an independent clinical trial replicated the finding that add-on allopurinol was effective in amelioration positive but not negative symptoms of schizophrenia in acute patients treated with haloperidol (287) . No significant central side effects were observed in either study. Despite these promising results, allopurinol should be, however, regarded as a treatment targeting purine metabolism in general rather than directly increasing adenosinergic transmission. Moreover, a recent case report by Gomberg (290) demonstrated a potential for allopurinol to cause a relapse in schizophrenic patients, i.e. recurrence of typical auditory hallucinations and paranoia was observed after one dose of allopurinol in a patient who was stable on clozapine and ziprasidone. In the light of the latter report, patients treated with such compounds should be carefully monitored for the recurrence or worsening of their symptoms. Therefore this fairly theoretical hypothesis of Lara et al. (5) needs further studies, since the role of adenosine in schizophrenia is still not well established.
A recent study by Brunstein et al. (291) gives support to the hypothesis postulating a dysfunction in adenosinergic activity in schizophrenia, which leads to synaptic adenosinergic deficit, possibly due to receptor modifications or altered metabolism (decreased production or increased degradation). The authors showed an increased activity of the enzyme adenosine deaminase in the serum of male schizophrenic patients under antipsychotic monotherapy. The observed elevation in serum adenosine deaminase activity may be, however, related to the disease itself (i.e. to altered adenosine metabolism in schizophrenic patients) or to the use of antipsychotics, especially clozapine (291).
In summary, it appears that manipulation of the endogenous level of adenosine may be of greater interest than selective activation of adenosine A 2A receptors. Indeed, the above-mentioned results indicate that therapeutics based on adenosine are of interest rather as modulators or enhancers of other more direct compounds, which in consequence leads to their lower doses and less adverse effects. 
Adenosine A 2A and dopamine D 3 receptor heteromers
Besides dopamine D 2 receptors, also D 3 receptors have been suggested to be involved in the pathogenesis of schizophrenia (292, 293) . The D 3 receptors are known to be mainly localized in limbic structures and several neuroleptics display high affinity for these receptors (293, 294) . In accordance with this opinion, Gurevich et al. (295) found a significant increase in the density of dopamine D 3 receptors in the ventral striatum of patients with schizophrenia. In addition, a significant decrease in the D 2 /D 3 binding in drug-naive schizophrenic patients in temporal cortex (296) as well as significant reductions in extrastratial (e.g. in the thalamus) D 2 /D 3 receptor availability (297) were also found.
Since D 3 receptors seem to be one of the therapeutic targets for treatment of schizophrenia (292, 293, 298) , the existence of such interaction between A 2A and D 3 receptors (see section 4.3.2.) could provide an alternative therapy. However, the possible existence of A 2A /D 3 heteromers in the e.g. ventral striatopallidal GABA neurons, and their functional interactions in the nucleus accumbens remain to be clarified.
Adenosine A 2A and mGlu5 receptor heteromers
The existence of heteromeric A 2A /mGlu5 receptor complexes seems to play an important modulatory role not only in the dorsal striatum but also in the function of the ventral striatopallidal GABA pathway (146) . Accordingly, the combined A 2A and mGlu5 receptors activation synergistically elevated extracellular GABA levels in the ventral pallidum after local co-perfusion with A 2A and mGlu5 receptor agonists (146) . Also behavioural studies have shown that co-administration of A 2A and mGlu5 receptor agonists counteracted the PCP-induced motor activity in rats, known to be mediated via D 2 receptor activity, which correlated with synergistic activation of c-Fos immunoreactivity in the nucleus accumbens (144) .
Taking into account the important modulatory role of mGlu5 receptors in schizophrenia (for details see 3.2.) it might be suggested that combined activation of mGlu5 and A 2A receptors may have a substantial antipsychotic action by overcoming the D 2 mediated inhibition of the ventral striatopallidal GABA pathway. By increasing the activity of cortical glutamatergic afferents from the mediodorsal thalamic nucleus to the prefrontal cortex, such treatment may enhance the glutamatergic transmission in the prefrontal cortex and in this way, may counteract the hypofrontality, observed in schizophrenia. However, this suggestion requires further examinations. 
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